MGI, a subsidiary of BGI Group,participated in the 29th European Conference on Microbiology and Infectious Diseases (ECCMID) in Amsterdam April 13-16. ECCMID is the world’s premier Clinical Microbiology & Infectious Diseases event, attracting many international experts from relevant fields.
A key topic of the conference was the urgent global need for diagnosis ,treatment and prevention of infectious diseasesof infectious diseases. Mgtagenomic Next Generation Sequencing Technology (mNGS)" provides a fast and accurate diagnostic basis for difficult and critical infections and guides the rational application of antibiotics.
Research from the big data clinical project of the Infectious Diseases
Department of Zhongshan Hospital and BGI was published on November 13, 2018 in Clinical Infectious Disease (IF=9.117).
Dr. Yao Yumeng and Dr. Liao Qing, members of a team led by Professor Hu Bijie of the Department of Infectious Diseases at Zhongshan Hospital (affiliated with Fudan University), spoke about “Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing when Applied to Clinical Practice.” Their research, published in the journal Clinical Infectious Disease (IF-9.117), shows that mNGS has vast potential in detecting infectious disease.
Dr. Yao introduced a big data clinical project in which Zhongshan Hospital and BGI have collaborated. The study collected 511 specimens from April 2017 to December 2017, including 347 cases of infectious diseases, 119 cases of non-infectious diseases and 45 unknown cases. Using the BGISEQ-50 sequencer, the study compared the differences
between mNGS and traditional culture methods in pathogen diagnostic efficacy and assessed the effect of antibiotics on detection rates through sample analysis, nucleic acid
extraction, library construction, DNA nanoball generation, sequencing, bioinformatics analysis and data annotation.
The research found that the sensitivity and specificity of mNGS for diagnosing infectious disease outperformed those of culture, especially for certain bacteria such as tuberculosis, viruses, anaerobes, and fungi. It also pointed to the advantage of mNGS technology for rapid diagnosis at the early stage, helping to guide further clinical diagnosis and treatment. The study reported the following conclusions:
1. The sensitivity and specificity of mNGS for diagnosing infectious disease were 50.7% and 85.7%, respectively, and these values outperformed those of culture, especially for Mycobacterium tuberculosis, viruses, anaerobes, and fungi.
2. Technology of mNGS can quickly report diagnosis results in the early stage, which can provide clues for further clinical diagnosis and treatment. It can effectively avoid the blind use of antibiotics especially when a virus infection exists.
3. The sensitivity of sputum specimen NGS is higher than that of culture (MTB, Aspergillus, Cryptococcus), and the sensitivity of BALF is higher than that of sputum specimens for NTM.
4. The effect of antibiotics on mNGS is much smaller than that of traditional bacterial culture methods, and the sensitivity of mNGS
A. The Effect of Prior Antibiotic Exposure on mNGS positivity
B. The Concordance of Initial Dx and mNGS
C.Pathogen Coverage of EAT
A Ratrospective Dx of All Cases B. Distribution of Sample Types
Performance at Pathogen Level
While the research results are based on BGISEQ-50 sequencer, at the conference MGI showed an advanced version of BGISEQ-50, the MGISEQ-200, as well as its new Microbiological Detection Total Solution, generating major interest from the global audience.
Technology of mNGS is in line with the concept of accurate diagnosis and treatment. It is vital to clarify the pathogens and promote the rational control of antibiotics in the era of drug resistance. Certainly, there are many aspects that need to be improved in mNGS, such as establishing specimen collection norms, standardizing of bioinformatics
analysis processes, and giving professional interpretations of text reports. In the future clinical practice, when combined with traditional microbial detection technology, mNGS will further promote popularization of rapid diagnosis of infection, guide the accurate selection of clinical antibacterial drugs, and contribute to the effective containment of bacterial resistance.
This research has demonstrated to the industry the huge potential of mNGS monitoring methods based on next generation sequencing in the field of infectious diseases. MGI has launched a comprehensive solution -- Microbiological Detection Total Solution -- that enables one-stop microbial identification of environmental or clinical samples without the need for separating cultures and empirical prediction. The microorganisms in the original sample can be classified and identified quickly, accurately and comprehensively, and the analysis results are automatically issued to provide reference for the diagnosis and treatment of infectious diseases. The program also offers a variety of microbiological testing solutions, thus users can choose hardware and supporting reagent supplies based on their own demands.
The launching of Microbiological Detection Total Solution enables easy use of mNGS detection methods, which are vital for improving infectious disease detection and promoting the diagnosis, treatment, prevention and control of infectious disease.